Systemic Therapy for Advanced Breast Cancer

Breast Journal

Volumn 10, Issue 1 SUPPL., 2004, Pages

  Tripathy, Debu ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; GEFITINIB; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PLATINUM DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN; VASCULOTROPIN ANTIBODY;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; IMMUNOHISTOCHEMISTRY; TOXICITY;

EID: 0942301285     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-4741.2004.101s9.x     Document Type: Conference Paper

References (6)

1. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999;18:2241-51.
2. Robert N, Leyland-Jones B, Asmar L, et al. Phase III randomized comparative study of trastuzumab and paclitaxel with and without carboplatinum in patients with HER2/neu positive advanced breast cancer [abstract 35]. Breast Cancer Res Treat 2002;76(suppl 1):S37.
3. Albain K, Elledge R, Gradishar R, et al. Open-label, phase II, multicenter trial of ZD1839 ("Iressa") in patients with advanced breast cancer [abstract 20]. Breast Cancer Res Treat 2002;76(suppl 1):S33.
4. Winer E, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva™ (erlotinib, OSI-774) in women with previously treated locally advanced or metastatic breast cancer [abstract 445]. Breast Cancer Res Treat 2002;76(suppl 1):S115.
5. Miller KD, Rugo H, Cobleigh M, et al. Phase III trial of capecitabine (Xeloda®) plus bevacizumab (Avastin™) versus capecitabine alone in women with metastatic breast cancer (MBC) previously treated with an anthracycline and a taxane [abstract]. Breast Cancer Res Treat 2002;76(suppl 1):S37.
6. Burstein HJ, Parker LM, Savoie J, et al. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer [abstract 446]. Breast Cancer Res Treat 2002;76(suppl 1):S116.